UNSPSC 51282916: Enrofloxacin

This classification denotes a quinolone antibiotic with the molecular formula C19H22FN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3DX3XEK1BN, chemically known as 1,4-dihydro-1-cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-4-oxo-3-quinolinecarboxylic acid but generally known as enrofloxacin, which bears US NIH Compound Identifier 71188. European Medicines Agency schedules Enrofloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06550MIG.

UNSPSC 51282916 Enrofloxacin (Commodity) shows minimal recent state and local procurement activity aligned with the code's nominal scope. The recent opportunities tagged to this code—including Naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription programs (Texas Health and Human Services Commission), medical and first aid supplies for fire rescue (City of Tampa), and generic multi-source pharmaceuticals through cooperative purchasing (Minnesota Multistate Cooperative Purchasing Alliance)—do not reflect procurement of enrofloxacin or veterinary pharmaceuticals. State and local governments do not appear to be actively soliciting this commodity through traditional procurement channels at present.

The mismatch between the code's specific pharmaceutical designation and the actual work being solicited suggests either a data-tagging error or that enrofloxacin procurement, if it occurs within state and local government, is conducted through channels not reflected in recent public notices. Firms pursuing work under this code should monitor cooperative purchasing vehicles such as MMCAP and state health agency solicitations for generic pharmaceuticals, as these represent the primary state and local mechanisms for acquiring pharmaceutical products, but should not expect near-term enrofloxacin-specific opportunities based on recent posting activity.